PROGRAMME OVERVIEW Saturday, October 13, 2018

Transcription

1 Saturday, October 13, 2018 Plenary Hall Meeting Room 26 Hall 1 Hall 2 Hall 3 Hall X Hall Y Hall Advisory Council Meeting Delegates Assembly 1 Radiopharmacy/ Drug Development Trial Regulations 6 / / ASNC Recent Guidelines on Myocardial Amyloidosis, Sarcoidosis and Large Vessel Vasculitis 2 Bone & / / GEMO Management of Bone Metastases in the Era of Targeted Treatments 7 / Physics Radiomics, AI and Machine Learning in Hybrid 3 Translational Molecular & The Role of Molecular in Radiation 8 / Physics Alpha- Endoradiotherapy in Solid Tumours 4 Physics Radiomics - Image Derived Parameters in Multimodality 9 / in Cancer 5 / INMiND Neuroinflammation in Neurodegeneration 10 Drug Development / Towards New Radiopharmaceuticals for Psychiatry Members Assembly :30-18:30 19:30-20:30 Opening 19:30-20:30 **Official approval of joint society pending as per date of printing 10 11

2 Sunday, October 14, Fever of Unknown Origin / ESPN The Role of Nuclear Medicine in Paediatric Febrile UTIs / EAU Update on the Use of PET/CT in Testicular Cancer 104 Opening (08:00-08:15) CTE 1 / SNMMI Prostate Cancer and : Tech Guide Launch Featured PRRT - Understand & Improve 106 SPECT-CT 107 Artefacts 1 - Bone & / Multimodality imaging in Sports Medicine Ga-PSMA it is! 110 From Myocardial Perfusion to Plaque 111 Walk 1 All Around Plenary 1 incl. Marie Curie Lecture In Vivo Molecular Diagnosis of Cognitive Disorders: A Paradigm Change New Guidelines in Nuclear ology / SIOPEN on Neuroblastoma / ESMI New Approaches for Atherosclerois 204 Plenary 1 incl. Marie Curie Lecture In Vivo Molecular Diagnosis of Cognitive Disorders: A Paradigm Change 304 CTE 2 - Radionuclide - A Multidisciplinary Approach 305 Therapie Effects, Preclinical 306 for 177 Lu-DOTA- Octreotate 307 Artefacts 2 - / Physics Artefacts in Hybrid Mix it up, Please! 311 Walk 2 PSMA - e-walk to Success? SPECT or PET? / / EULAR Guidelines on Vasculitis / ISNS / EHNS What is Changing in the Sentinel Node Procedure? 404a Mini Course 1 (-) Non- Nuclear Medicine Diagnostic 404b Mini Course 2 (15:45-16:45) Lymphoscintigraphy and Sentinel Node 405 PSMA Targeting 406 Image Processing / Analysis Basics of 408 Special 20 Years of PET/CT in Practice 409 Targeted of Malignant Tumours 411 Walk PET/MR in Sharing Experiences / EAN / SNMMI Trials in Dementia - Expectations on Molecular / IASLC New Techniques for Diagnosis and Prognostication of Lung Cancer Patients 404c Mini Course 3 - ( - ) PET Patient Preparation: Artefacts 505 PSMA - Expanding Effects 506 Standardization & Calibration Lung Anatomy and Patterns of Lung Malignancy 508 PRRT of Neuroendocrine Tumours 509 Endocrine 510 New Trends in & Inflammation 511 Walk 4 Bone & Scintillating Bone - - *ICC = Cases **Official approval of joint society pending as per date of printing 12 13

3 Monday, October 15, Radiopharmacy / EDQM Validation of Radioanalytical Methods / ESVS Inside the Aorta: Vascular Inflammation, and Atherosclerosis / ESMO Radioisotope Therapies in Prostate Cancer and Position in Oncological Treatment Paradigms 604 Presentations It s All About Peptides 606 Radiation Exposure & Protection 607 Artefacts 3 - Advantages and Limitations of Voxelized for Intra- Arterial Liver It s in the Blood! 609 Endocrine Molecular 610 Integrating Models in MPI - From Injection to Interpretation 611 Walk 5 Instrumentation & Data Analysis Plenary 2 To Do, or Not to Do, that is the Question Alpha Particle - When, Why and How? / ATA tbc / EORTC Integrating PET into RECIST 704 Plenary 2 To Do, or Not to Do, that is the Question 804 (in Rooms 31-34) Technologist Walks Reconstruction 807 Artefacts 4 - / Physics Amyloid GIT up! 809 Special Tomorrow s Experts Best-Ranked Papers from the Under-30s Radiation Protection / Optimization of Diagnostic Reference Levels in Hybrid in Paediatric / Drug Development / ECNP Phosphodiesterases (PDEs) in the CNS: Targets for Drug Development / EHA PET/CT Guided Treament in Hodgkin Lymphoma 904 CTE 3 / in Dementia 905 Antibodies & Peptides: Let s Modify! 906 in PSMA - What is the Benefit? ESMIT Modern Insight in Medical Education 909 Radioiodine of Benign Diseases Radiopharmacy / / Radiation Protection / EMA tbc. 911 Walk 6 Different Aspects of I Different Strategies in the Management of Hepatic Metastases in NEN / ASNC Detecting Cardiac Microvascular Disease with PET Physics / EFOMP / ESR Dedicated and Low Dose Molecular 1004 CTE 4 Latest Development in PET/MR 1005 Antibodies and their Fragments 1006 Alpha-Particle Emitter Lung TNM 8 and Function of the Lung MDM 1008 PSMA Ligand of Prostate Cancer 1009 Cancer - From Pathology to Personalized Treatment Cognitive Impairment & Neuro-Degeneration 1011 Walk 7 & InflammationI - - *ICC = Cases **Official approval of joint society pending as per date of printing 14 15

4 Tuesday, October 16, & / Targets for Cancer Immunotherapy / ICRU Target Practice - Conditions for Personalized Treatment Planning in Radionuclide / JSNM Targeted Alpha - Prospect of Networking, Partnership, and Logistics 1104 Presentations AD-PD - It s in the brain! 1106 Data Analysis - Neurology 1107 Artefacts 5 - Pitfalls in Parathyroid Detection with Nuclear Medicine Prostate - Not Just 68Ga-PSMA 1109 Other Studies Non 1110 Myocardial with SPECT and PET 1111 Walk 8 / Other Studies / Other Studies Plenary 3 The Fascinating World of Molecules Bone & How Much Radiology Do We Need in Bone and Multi- Modality? / EANO Meningioma / EACVI Quantification of Myocardial Blood Flow 1204 Plenary 3 The Fascinating World of Molecules 1304 Presentations Therapie Effects - α Emitters and PDT Quantification & Data Analysis 1307 Artefacts 6 - Translational Molecular & Is this Uptake Pathological or is it Due to Excretion? Lung! Lung! Lung! Featured Scintigraphy - An Evergreen 1311 Walk Update on PET/MR in & / AHA Early Remodelling in Cardiomyopathies - From Preclinical to / ETA / EUGOGO Treatment of Graves Disease (GD) in the Presence of Graves Ophthalmopathy (GO) 1404 CTE 5 / ESTRO PET/CT Radiotherapy Planning in Head & Neck Malignancies 1406 Methodologies - From Images to Absorbed Dose Radiopharmacy Nanomedicine and Radiopharmaceuticals 1408 Radioligand of Neuroendocrine Tumours - Safety & Toxicity Walk 10 Quality Control & Radiopharmaceutical Aspects PET Guided Biopsy /EARL New Developments of PET/CT Guidelines and Update of the EARL Accreditation Standards / ETA-CRN Molecular Mechanism of Iodine Resistance and Their Implications 1504 CTE 6 - Renal 1505 Novel Tracers in 1506 Treatment Planning for Y-90 Radioembolisation Lung Cancer Testing your Knowledge with Live Cases In the Air and Beyond 1510 Myocardial - New Developments with CZT-Cameras 1511 Walk 11 Mixer - - *ICC = Cases **Official approval of joint society pending as per date of printing 16 17

5 Wednesday, October 17, / Myocardial 123-mIBG in Neurology Is it Ready for Prime Time? Radiation Protection / / / ICRP Risk Estimates for Patients Undergoing Molecular Radionuclide & / IFCARS Computer Assisted Image and Radioguided Intervention in Surgery and Radiology 1605 Neuroinflammation & Brain 1606 PET-CT & PET-MR 1607 Artefacts 7 - PSMA Women ONLY! 1611 Walk 12 Different Aspects of II Physics / Quantitative Multimodality 1801 Awards (11:45-12:15) Plenary 4 - Highlights Lecture (12:15-13:15) Closing (13:15-13:20) / EACVI The Potential of Dual Isotope in Nuclear Cardiology / ESTRO PET/CT for Radiotherapy Planning 1704 CTE 7 - / and 1804 Awards (11:45-12:15) Plenary 4 - Highlights Lecture (12:15-13:15) Closing (13:15-13:20) 1705 Radiochemistry is Cool! 1706 Miscellaneous Topics in 1709 Dementia 1710 Bone & - Featured Bone & Hybrid 1711 Walk 13 Radionuclide / Local and Systemic of Malignant Tumours *ICC = Cases **Official approval of joint society pending as per date of printing 18 19